Antibodies to Factor XII Are Distinct from Antibodies to Prothrombin in Patients with the Anti-phospholipid Syndrome

Summary

Patients with the anti-phospholipid syndrome (APS) have antiphospholipid antibodies (aPA) which are often targeted towards phospholipid binding proteins such as β2-glycoprotein I and prothrombin. Antibodies to factor XII (FXIIabs) have also been identified in some patients with APS. Factor XII (FXII) is a member of the kringle family of proteins which include plasminogen and prothrombin. Antibodies to prothrombin have been associated with myocardial infarction and have been shown to cross react with plasminogen.

Sixteen patients with APS and FXIIabs were investigated for the presence of antibodies to prothrombin, by enzyme linked immunosorbent assay in a calcium (Ca⁺⁺) independent assay. All sixteen showed different antibody binding patterns than those observed for antibodies to FXII.

Eight patients were further investigated using surface plasmon resonance (SPR) for antibody binding to covalently bound FXII and to covalently bound prothrombin in both Ca⁺⁺ dependent and independent systems. Of three patients demonstrating antibody binding to FXII by SPR, none demonstrated antibody binding to prothrombin in a Ca⁺⁺ independent system with one demonstrating antibody binding to prothrombin that was Ca⁺⁺ dependent. Of five patients who did not bind FXII by SPR, one demonstrated antibody binding to prothrombin in a Ca⁺⁺ independent system while two demonstrated antibody binding to prothrombin in a Ca⁺⁺ dependent system. Antibodies to FXII in patients with APS appear to be distinct from antibodies to prothrombin.

Keywords

Factor XII - anti-phospholipid syndrome - prothrombin - antibodies to factor XII

• References

• 1 Hughes GRV. Thrombosis, abortion, cerebral disease and lupus anticoagulant. B M J 1983; 187: 1088-9.
• 2 Galli M, Confurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, Barbui T, Zwaal RF, Bevers EM. Anticardiolipin antibodies are directed not to cardiolipin but to a plasma protein co-factor. Lancet 1990; 335: 1544-7.
• 3 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β₂-glycoprotein I. Proc Natl Acad Sci USA 1990; 87: 4120-4.
• 4 Matsuura E, Igarashi T, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin co-factor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8.
• 5 Bevers EM, Galli M, Barbui T, Confurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
• 6 Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognise a kininogen-PE complex. Blood 1995; 86: 3083-9.
• 7 Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in kininogens recognisable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996; 76: 354-60.
• 8 Jones DW, Gallimore MJ, Harris SL, Winter M. 1999; Antibodies to factor XII associated with lupus anticoagulant. Thromb Haemost 81: 387-90.
• 9 Vaarala O, Puurunen M, Mänttäri M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middleaged men. Thromb Haemost 1996; 75: 456-9.
• 10 Puurunen M, Mänttäri M, Manninen V, Palosuo T, Vaarala O. Antibodies to prothrombin cross react with plasminogen in patients developing myocardial infarction. Br J Haematol 1998; 100: 374-9.
• 11 Gailani D, Broze Jr JR. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-12.
• 12 Kluft C, Dooijewaard G, Emeis JJ. Role of the contact system in fibrinolysis. Semin Thromb Haemost 1987; 13: 50-68.
• 13 Smith O, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 1985; 66: 835-9.
• 14 Bradford HN, Pixley RA, Colman RW. Human factor XII binding to the glycoprotein Ib-IX-V complex inhibits thrombin-induced platelet aggregation. J Biol Chem 2000; 275: 22756-63.
• 15 Jones DW, Gallimore MJ, Mackie IJ, Harris SL, Winter M. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol 2000; 110: 721-6.
• 16 Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GRV, Triplett DA, Khamashta MA. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis and Rheum 1999; 42: 1309-11.
• 17 Greaves M. Antiphospholipid antibodies and thrombosis. Lancet 1999; 353: 1348-53.
• 18 Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinaemia of the acquired hypoprothrombinaemialupus anticoagulant syndrome. Blood 1983; 61: 684-92.
• 19 Borowski M, Furie BC, Bauminger S, Furie B. Prothrombin requires two sequential metal-dependant conformational transitions to bind phospholipid. Conformation-specific antibodies directed against phosphlipid-binding site on prothrombin. J Biol Chem 1986; 261: 14969-75.
• 20 Quinn JG, O’Kennedy R, Smyth M, Moulds J, Frame T. Detection of blood group antigens utilising immobilised antibodies and surface plasmon resonance. J Immunol Methods 1997; 206: 87-96.
• 21 Guerin J, Smith O, White B, Sweetman G, Feighery C, Jackson J. Antibodies to prothrombin in antiphospholipid syndrome and inflammatory disorders. Br J Haematol 1998; 102: 896-902.
• 22 Galli M, Barbui T. Antiprothrombin antibodies: Detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93: 2149-57.
• 23 Jones DW, Mackie IJ, Gallimore MJ, Winter M. Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol 2001; 113: 550-2.